Completed PHASE4 INTERVENTIONAL NCT00297310

Pre-transplant Assessment of Tacrolimus Blood Level Concentration, as a Predictor of Tacrolimus Dose Requirements After Kidney Transplantation

Pre-transplant Pharmacokinetics as a Predictor of the Tacrolimus Dose Requirement Post Renal Transplantation

Sponsor: Janssen-Cilag Pty Ltd

Conditions Kidney Transplantation Transplantation

Interventions tacrolimus

Updated 6 times since 2017 Last updated: Jun 6, 2011 Started: May 31, 2004 Primary completion: Oct 31, 2006 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Kidney Transplantation and Transplantation, this trial is completed. The trial is conducted by Janssen-Cilag Pty Ltd and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Apr 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Apr 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag Pty Ltd

Data source: Janssen-Cilag Pty Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.